Alpha Tau to Present at the Jefferies Radiopharma Innovation Summit
March 25, 2024 08:50 ET
|
Alpha Tau Medical Ltd.
JERUSALEM, March 25, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha...
Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update
March 07, 2024 16:01 ET
|
Alpha Tau Medical Ltd.
- Positive interim safety and feasibility data from pancreatic cancer study in Montreal, with initial signs of potential dose response findings - - ReSTART U.S. multi-center pivotal trial currently...
Alpha Tau to Participate in Barclays 26th Annual Global Healthcare Conference
February 26, 2024 08:30 ET
|
Alpha Tau Medical Ltd.
JERUSALEM, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™,...
Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 20, 2023 09:15 ET
|
Alpha Tau Medical Ltd.
- The overview presentation will review some of the Company’s recent achievements, including highly promising interim results from the Company’s pancreatic cancer safety and feasibility trial as well...
Alpha Tau to Participate in Sidoti Small-Cap Conference
November 29, 2023 08:30 ET
|
Alpha Tau Medical Ltd.
JERUSALEM, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™,...
Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer
November 28, 2023 08:30 ET
|
Alpha Tau Medical Ltd.
- Interim data read-out of the first five treated patients demonstrated successful delivery in all five cases, as well as no product-related Serious Adverse Events - - First five patients received...
Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer
November 20, 2023 08:30 ET
|
Alpha Tau Medical Ltd.
JERUSALEM, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau") (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, and HekaBio K.K....
Alpha Tau Medical Announces Third Quarter 2023 Financial Results and Provides Corporate Update
November 16, 2023 16:30 ET
|
Alpha Tau Medical Ltd.
- Treated the first patient with advanced inoperable pancreatic cancer at Hadassah Medical Center in Israel in September, alongside safety and feasibility trial in similar indication currently...
Alpha Tau to Participate in November Investor Conferences
November 01, 2023 08:30 ET
|
Alpha Tau Medical Ltd.
JERUSALEM, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™,...
Alpha Tau Enters Into Long-Term Lease of Site in New Hampshire for Second U.S. Manufacturing Facility
October 30, 2023 08:30 ET
|
Alpha Tau Medical Ltd.
JERUSALEM, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™,...